Literature DB >> 28114252

Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation.

Freddy E Escorcia1, Michael A Postow, Christopher A Barker.   

Abstract

Radiotherapy and immune checkpoint blockade are effective treatments for melanoma. Recent preclinical studies have suggested an interaction of radiotherapy and immune checkpoint blockade. Retrospective clinical studies, as well as a small number of prospective studies, have been undertaken to explore this interaction in patients with melanoma. In this review, we present the results of clinical studies combining radiotherapy and immune checkpoint blockade and conclude that this is a promising strategy worth of further investigation.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28114252      PMCID： PMC5300083          DOI： 10.1097/PPO.0000000000000236

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  37 in total

1.  Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies.

Authors:  Stephanie Du Four; Sofie Wilgenhof; Johnny Duerinck; Alex Michotte; Anne Van Binst; Mark De Ridder; Bart Neyns
Journal:  Eur J Cancer       Date:  2012-06-22       Impact factor: 9.162

2.  Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

Authors:  Ana P Kiess; Jedd D Wolchok; Christopher A Barker; Michael A Postow; Viviane Tabar; Jason T Huse; Timothy A Chan; Yoshiya Yamada; Kathryn Beal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-05       Impact factor: 7.038

Review 3.  Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

Authors:  Christopher A Barker; Michael A Postow; Shaheer A Khan; Kathryn Beal; Preeti K Parhar; Yoshiya Yamada; Nancy Y Lee; Jedd D Wolchok
Journal:  Cancer Immunol Res       Date:  2013-07-25       Impact factor: 11.151

4.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

5.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

6.  A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.

Authors:  Susan M Hiniker; Sunil A Reddy; Holden T Maecker; Priyanka B Subrahmanyam; Yael Rosenberg-Hasson; Susan M Swetter; Saurabh Saha; Lei Shura; Susan J Knox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-15       Impact factor: 7.038

7.  Stereotactic Radiosurgery: Treatment of Brain Metastasis Without Interruption of Systemic Therapy.

Authors:  Colette J Shen; Megan N Kummerlowe; Kristin J Redmond; Daniele Rigamonti; Michael K Lim; Lawrence R Kleinberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-09       Impact factor: 7.038

8.  Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.

Authors:  Maya Mathew; Moses Tam; Patrick A Ott; Anna C Pavlick; Stephen C Rush; Bernadine R Donahue; John G Golfinos; Erik C Parker; Paul P Huang; Ashwatha Narayana
Journal:  Melanoma Res       Date:  2013-06       Impact factor: 3.599

9.  The abscopal effect associated with a systemic anti-melanoma immune response.

Authors:  Emily F Stamell; Jedd D Wolchok; Sacha Gnjatic; Nancy Y Lee; Isaac Brownell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-05       Impact factor: 7.038

10.  Ipilimumab and radiation therapy for melanoma brain metastases.

Authors:  Ann W Silk; Michael F Bassetti; Brady T West; Christina I Tsien; Christopher D Lao
Journal:  Cancer Med       Date:  2013-10-10       Impact factor: 4.452
View more
  10 in total

1.  The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.

Authors:  Filipe Martins; Luis Schiappacasse; Marc Levivier; Constantin Tuleasca; Michel A Cuendet; Veronica Aedo-Lopez; Bianca Gautron Moura; Krisztian Homicsko; Adrienne Bettini; Gregoire Berthod; Camille L Gérard; Alexandre Wicky; Jean Bourhis; Olivier Michielin
Journal:  J Neurooncol       Date:  2019-12-14       Impact factor: 4.130

2.  Brain Metastases from Esophageal Squamous Cell Carcinoma: Clinical Characteristics and Prognosis.

Authors:  Linlin Xiao; Yvonne M Mowery; Brian G Czito; Yajing Wu; Guangbin Gao; Chang Zhai; Jianing Wang; Jun Wang
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

3.  Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.

Authors:  Silvia Scoccianti; Emanuela Olmetto; Valentina Pinzi; Mattia Falchetto Osti; Rossella Di Franco; Saverio Caini; Paola Anselmo; Paolo Matteucci; Davide Franceschini; Cristina Mantovani; Giancarlo Beltramo; Francesco Pasqualetti; Alessio Bruni; Paolo Tini; Emilia Giudice; Patrizia Ciammella; Anna Merlotti; Sara Pedretti; Marianna Trignani; Marco Krengli; Niccolò Giaj-Levra; Isacco Desideri; Guido Pecchioli; Paolo Muto; Ernesto Maranzano; Laura Fariselli; Pierina Navarria; Umberto Ricardi; Vieri Scotti; Lorenzo Livi
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

4.  Cytokine release syndrome after radiation therapy: case report and review of the literature.

Authors:  Christopher A Barker; Samuel K Kim; Sadna Budhu; Konstantina Matsoukas; Anthony F Daniyan; Sandra P D'Angelo
Journal:  J Immunother Cancer       Date:  2018-01-03       Impact factor: 13.751

Review 5.  Radiotherapy for Melanoma: More than DNA Damage.

Authors:  Susanne J Rogers; Emsad Puric; Brigitte Eberle; Niloy R Datta; Stephan B Bodis
Journal:  Dermatol Res Pract       Date:  2019-04-03

Review 6.  Neoadjuvant therapy of locally/regionally advanced melanoma.

Authors:  Arjun Khunger; Zachary S Buchwald; Michael Lowe; Mohammad K Khan; Keith A Delman; Ahmad A Tarhini
Journal:  Ther Adv Med Oncol       Date:  2019-07-31       Impact factor: 8.168

Review 7.  The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review.

Authors:  Barbara Seliger
Journal:  Front Immunol       Date:  2019-09-06       Impact factor: 7.561

8.  Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature.

Authors:  Tsubasa Watanabe; Elke Firat; Jutta Scholber; Simone Gaedicke; Corinne Heinrich; Ren Luo; Nicolas Ehrat; Gabriele Multhoff; Annette Schmitt-Graeff; Anca-Ligia Grosu; Amir Abdollahi; Jessica C Hassel; Dagmar von Bubnoff; Frank Meiss; Gabriele Niedermann
Journal:  Cancer Immunol Immunother       Date:  2020-04-29       Impact factor: 6.968

9.  Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors.

Authors:  Hemanth K Potluri; Carolina A Ferreira; Joseph Grudzinski; Christopher Massey; Eduardo Aluicio-Sarduy; Jonathan W Engle; Ohyun Kwon; Ian R Marsh; Bryan P Bednarz; Reinier Hernandez; Jamey P Weichert; Douglas G McNeel
Journal:  J Immunother Cancer       Date:  2022-08       Impact factor: 12.469

10.  Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.

Authors:  Danielle M Lussier; Elise Alspach; Jeffrey P Ward; Alexander P Miceli; Daniele Runci; J Michael White; Cedric Mpoy; Cora D Arthur; Heather N Kohlmiller; Tyler Jacks; Maxim N Artyomov; Buck E Rogers; Robert D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-15       Impact factor: 11.205
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.